Investor Presentation First Nine Months of 2022
124
Investor presentation First nine months of 2022
Region China remains a key strategic opportunity
Region China is a large market with
~140 million people living with diabetes
22%
23%
78%
77%
Sales
Region China
Patients
Rest of IO
•
.
•
Region China
Outcome of VBP insulin in China
Price cuts ~40-50% as a result of VBP
Keeps -50% of own brand volume in scope
Resource re-allocation towards growth
products
Opportunities and strategic priorities
•
•
Large growing diabetes market
Market of 26 bDKK mainly
consisting of OAD and insulin
Diabetes market growth of -11%
TRESIBA
insulin degludec [rDNA origin] injection
human insulin MixtardⓇ30
biphasic insulin
NovoMix®
(biphasic insulin aspart)
LevemirⓇ
(insulin detemir)
Novo Rapid
(insulin aspart)
Bring innovation faster to market
Diabetes: RybelsusⓇ and
ONWARDS programme for Icodec
Rare disease: Across portfolio
RYZODEG
70% insulin degludec and 30% insulin aspart
[rDNA origin] injection
Xultophy
insulin degludec/liraglutide
[rDNA origin] injection
OZEMPİC
semaglutide injection
Treat more patients
Expand patient base across new
insulins and GLP-1s
Note: IQVIA value in China only covers -60% of the market
Region China includes Mainland China, Taiwan and Hong Kong; VBP: Volume-based procurement; OAD: Oral anti-diabetes; IO: International Operations
Source: Full year 2021 numbers based on Company Announcement (sales) and Diabetes Atlas, 10th edition, (patients)View entire presentation